Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -73.66% is 19% above its 4-year average of -91.42%, near the high end of its 4-year range (-307.91%–-24.50%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.30% below its 12-month average of -64.45%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -73.66%.
RETURN ON EQUITY (ROE)
-73.66%
RETURN ON EQUITY (ROE) AVG TTM
-64.45%
RETURN ON EQUITY (ROE) AVG 3Y
-124.57%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-14.30%
CURRENT VS 3Y AVG
+40.87%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-92.59%
vs the sector median at left
Bone Biologics Corporation
Market Cap
$897948.00
Return on Equity (ROE)
-73.66%
TTM Avg
-64.45%
3Y Avg
-124.57%
5Y Avg
N/A
Market Cap
$893920.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$877747.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$815044.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
Market Cap
$1.01M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$693655.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
Market Cap
$1.09M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$1.14M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $897948.00 | -73.66% | -64.45% | -124.57% | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | -255.88% | -273.58% | -200.54% |
| Decoy Therapeutics Inc. (DCOY)vs › | $877747.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $815044.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -93.97% | 234.49% | 123.23% | 1171.22% |
| CDT Equity Inc. (CDT)vs › | $693655.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | -57.87% | -222.45% | -164.72% | -135.78% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -11.85% | -6.20% | 47.36% | 47.36% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | N/A | 206.72% | 141.32% | 115.74% |
ROE
-73.7%
ROA
-65.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -73.66% |
| 2026-03-31 | -61.20% |
| 2025-12-31 | -57.81% |
| 2025-09-30 | -65.59% |
| 2025-06-30 | -63.98% |
| 2025-03-31 | -146.47% |
| 2024-12-31 | -118.05% |
| 2024-09-30 | -109.18% |
| 2024-06-30 | -176.00% |
| 2024-03-31 | -166.12% |
| 2023-12-31 | -307.91% |
| 2023-09-30 | -171.51% |
| 2023-06-30 | -101.96% |
| 2023-03-31 | -162.49% |
| 2022-12-31 | -24.96% |
| 2022-09-30 | -58.06% |
| 2022-06-30 | -33.03% |
| 2022-03-31 | -30.94% |
| 2021-12-31 | -24.50% |
